Zobrazeno 1 - 5
of 5
pro vyhledávání: '"P. Jolonch Santasusagna"'
Autor:
E. de Puig Cabrera, P. Jolonch Santasusagna, C. Codina Jané, F. Pàez Vives, J. Gómez-Arbonés, E. Homs Peipoch, MQ Gorgas Torner, JA Schoenenberger Arnaiz, J. Camós Ramió
Publikováno v:
Farmacia Hospitalaria. 36:229-239
Objectives: To assess whether an integrated pharmaceutical care programme (IPCP) improves clinical evolution, patient quality of life, and reduces health costs in chronic patients. Material and methods: A parallel, open, and multi-centre clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c48076a6f40db39635d089ffb6c0fe3
https://doi.org/10.1016/j.farma.2011.06.015
https://doi.org/10.1016/j.farma.2011.06.015
Autor:
P. Jolonch Santasusagna, M Canela Subirada, C Ros Bertomeu, M Martín Marqués, M Duran Taberna, N Gotanegra Guzmán
Publikováno v:
European Journal of Hospital Pharmacy. 23:A246.2-A247
Background Patient safety by improving the use of chronic medications requires coordination between levels of care. New anticoagulants (NACOS) are high risk drugs that require systematic processes that allow review of their adequacy and safety. Purpo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14a546de324b0d090ef605a98256a895
https://doi.org/10.1136/ejhpharm-2016-000875.559
https://doi.org/10.1136/ejhpharm-2016-000875.559
Autor:
M Q, Gorgas Torner, F, Pàez Vives, J, Camós Ramió, E, de Puig Cabrera, P, Jolonch Santasusagna, E, Homs Peipoch, J A, Schoenenberger Arnaiz, C, Codina Jané, J, Gómez-Arbonés
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 36(4)
To assess whether an integrated pharmaceutical care programme (IPCP) improves clinical evolution, patient quality of life, and reduces health costs in chronic patients.A parallel, open, and multi-centre clinical trial of an IPCP in patients with hear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f39fb931e4fe1e9049fec4aa2e398ad6
https://pubmed.ncbi.nlm.nih.gov/23461510
https://pubmed.ncbi.nlm.nih.gov/23461510
Autor:
I. Martinez Martinez, E. Vicente Escrig, B. Rodriguez Carballo, P. Jolonch Santasusagna, M.C. Gomez Blasco
Publikováno v:
European Journal of Hospital Pharmacy. 19:171.1-171
Background A novel target for the treatment of rheumatoid arthritis (RA) is cytokine interleukin-6 (IL-6), a key pro-inflammatory cytokine in RA contributing to both the articular and systemic manifestations of the disease. Purpose To describe the ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4cb1d37e80e664582ae50b64fab83a7
https://doi.org/10.1136/ejhpharm-2012-000074.226
https://doi.org/10.1136/ejhpharm-2012-000074.226
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.